India health ministry considers biosimilar regs; 3 generics makers weigh Teva portfolio bid;

> India's health ministry said it plans to take a new look at regulations governing biosimilars and will focus on areas such as comparability tests and postmarketing surveillance. Report

> Thermo Fisher Scientific said it has opened a new GMP clinical services facility in Singapore to serve regional and global customers with facilities for storage, local labeling, secondary packaging, returns management and other services. Release

> Three Indian generic drug makers are said to be exploring bids for a portfolio of products being put on the block by Teva Pharmaceutical Industries ($TEVA) as the company tries to gain antitrust approval for its $40.5 billion bid for Allergan's ($AGN) generics business, according to a Bloomberg report. The wire service said Glenmark Pharmaceuticals, Sun Pharmaceutical Industries and Cipla are all weighing their options on a deal that could be worth up to $800 million. Report

> Dr. Reddy's Laboratories ($RDY) said it has completed its acquisition of IP rights for the anticoagulant generic Fondaparinux sodium from Australia's Alchemica for about $17.5 million, Live Mint reported. Report

> Global spending on medications will grow by as much as 32% by 2020 and could hit $1.4 trillion, a new report from the IMS Institute for Healthcare Informatics said, adding that the "medicine use gap" between developed and developing countries narrows. Report

> Japan's health ministry is looking to further cut mandated prices on generic drugs to expand their use and cut rising healthcare costs. Report

> The World Health Organization said a recent survey showed rising concerns over the online sale of antibiotics in India as well as overuse of the drugs for common ailments like colds and the flu. Report

> Indian drugmakers are worried over reports that China is tying its foreign aid to Africa, Eastern Europe and countries in Asia to conditions that may exclude Indian companies in favor of Chinese pharmaceutical companies. Report